Spero Therapeutics, Inc.

Total Valuation

Spero Therapeutics, Inc. carries a market capitalization of 162.12M, placing it among publicly traded companies globally. Its enterprise value stands at 78.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Spero Therapeutics, Inc. currently has 57.89M shares outstanding.

Valuation Ratios

Spero Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 8.66. The price-to-sales ratio is 2.41, and the price-to-book ratio stands at -0.29.

Enterprise Valuation

On an enterprise value basis, Spero Therapeutics, Inc. trades at an EV/EBITDA multiple of 5.52 and an EV/FCF ratio of 10.82. The EV/Sales ratio of 1.43 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.52 provides insight into valuation relative to core operating earnings.

Financial Position

Spero Therapeutics, Inc. maintains a current ratio of 10.50, meaning it holds 10.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Spero Therapeutics, Inc. has paid 261,000.00 in income taxes, reflecting an effective tax rate of 1.68.

Stock Price Statistics

Spero Therapeutics, Inc.'s stock has gained approximately 6.06061% over the past 52 weeks. The 50-day moving average sits at 2.63, while the 200-day moving average is 2.35.

Income Statement

Over the trailing twelve months, Spero Therapeutics, Inc. generated 54.77M in revenue and converted that into 15.24M in net income, yielding earnings per share of 0.27. EBITDA reached 14.18M, while operating income came in at 14.18M.

Balance Sheet

Spero Therapeutics, Inc. holds 56.13M in cash and equivalents against 2.47M in total debt, resulting in a net debt position of -56.13M. Total book value stands at -458.21M, with working capital of 52.12M providing operational flexibility.

Cash Flow

Spero Therapeutics, Inc. produced 7.24M in operating cash flow over the past twelve months.

Margins

Spero Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 25.89 and net profit margin of 27.82 provide insight into operational efficiency.

Dividends & Yields

Scores

Spero Therapeutics, Inc. posts an Altman Z-Score of 4.92, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.